Hemostemix Inc.

Hemostemix Inc is a Canada based clinical-stage biotechnology company. Its principal business activity is to develop, manufacture and commercialize blood-derived cell therapies for medical conditions. The company’s technology platform for developing autologous cell therapies is for treatment of vascular diseases. The group’s clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of critical limb ischemia.